Daniel Soares
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Soares has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ana Beatriz Pérez
Cellular Immunology Laboratory, Virology Department, Tropical Medicine Institute “Pedro Kourí”, Autopista Novia del Medio Día Km 6 ½, La Habana 11400, Cuba
1 shared publication - Ana Cristina Magalhaes
I3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
1 shared publication - Beatriz Sierra
Virology Department, "Pedro Kourí" Tropical Medicine Institute (IPK). Autopista Novia del Mediodía, km 61/2.Havana, Cuba
1 shared publication - Bruno Cavadas
I3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
1 shared publication - Claudia Bracho
Virology Department, PAHO/WHO Collaborating Center for the Study of Dengue and Its Vector, Pedro Kourí Institute of Tropical Medicine (IPK), Havana 11400, Cuba
1 shared publication - Eglis Aguirre
Virology Department, PAHO/WHO Collaborating Center for the Study of Dengue and Its Vector, Pedro Kourí Institute of Tropical Medicine (IPK), Havana 11400, Cuba
1 shared publication
Latest Publications
- Open Access
Multi-Tissue Transcriptomic-Informed In Silico Investigation of Drugs for the Treatment of Dengue Fever Disease
Transcriptomics, proteomics and pathogen-host interactomics data are being explored for the in silico–informed selection of drugs, prior to their functional evaluation. The effectiveness of this kind of strategy has been put to the test in the current COVID-19 pandemic, and it has been paying off, leading to a few drugs being rapidly repurposed as treatment against SARS-CoV-2 infection. Several neglected tropical diseases, for which treatment remains unavailable, would benefit from informed in silico investigations of drugs, as performed in this work for Dengue fever disease. We analyzed transcriptomic data in the key tissues of liver, spleen and blood profiles and verified that despite transcriptomic differences due to tissue specialization, the common mechanisms of action, “Adrenergic receptor antagonist”, “ATPase inhibitor”, “NF-kB pathway inhibitor” and “Serotonin receptor antagonist”, were identified as druggable (e.g., oxprenolol, digoxin, auranofin and palonosetron, respectively) to oppose the effects of severe Dengue infection in these tissues. These are good candidates for future functional evaluation and clinical trials.
Open AccessMulti-Tissue Transcriptomic-Informed In Silico Investigation of Drugs for the Treatment of Dengue Fever Disease
Transcriptomics, proteomics and pathogen-host interactomics data are being explored for the in silico–informed selection of drugs, prior to their functional evaluation. The effectiveness of this kind of strategy has been put to the test in the current COVID-19 pandemic, and it has been paying off, leading to a few drugs being rapidly repurposed as treatment against SARS-CoV-2 infection. Several neglected tropical diseases, for which treatment remains unavailable, would benefit from informed in silico investigations of drugs, as performed in this work for Dengue fever disease. We analyzed transcriptomic data in the key tissues of liver, spleen and blood profiles and verified that despite transcriptomic differences due to tissue specialization, the common mechanisms of action, “Adrenergic receptor antagonist”, “ATPase inhibitor”, “NF-kB pathway inhibitor” and “Serotonin receptor antagonist”, were identified as druggable (e.g., oxprenolol, digoxin, auranofin and palonosetron, respectively) to oppose the effects of severe Dengue infection in these tissues. These are good candidates for future functional evaluation and clinical trials.